Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Titel:
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Auteur:
Hungria, Vania Robak, Paweł Hus, Marek Zherebtsova, Vera Ward, Christopher Ho, P Joy Hájek, Roman Kim, Kihyun Grosicki, Sebastian Sia, Hanlon Bryant, Adam Pitombeira de Lacerda, Marcelo Martinez, Gracia Aparecida Sureda Balarí, Anna Sandhu, Irwindeep Cerchione, Claudio Ganly, Peter Dimopoulos, Meletios A Fu, Chengcheng Garg, Mamta Abdallah, Al-Ola Gatt, Moshe E Oriol Rocafiguera, Albert Cavo, Michele Rifkin, Robert Fujisaki, Tomoaki Mielnik, Michał Ficek, Joseph Mantero, Alejandro Pirooz, Nick Varghese, Sybil Lee, Joe McKeown, Astrid Rogers, Rachel Baig, Hena Eccersley, Lydia Roy-Ghanta, Sumita Mukhopadhyay, Pralay Nielsen, Jacqueline Opalinska, Joanna Mateos, María-Victoria